Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03221426
Title Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


Capecitabine + Cisplatin

Capecitabine + Cisplatin + Pembrolizumab

Cisplatin + Fluorouracil + Pembrolizumab

Cisplatin + Fluorouracil

Age Groups: adult | senior
Covered Countries USA | CAN

No variant requirements are available.